SCHEMBL24616134

SCHEMBL24616134

Oc1nc(O)c2cc(Cl)c(Br)c(Cl)c2n1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22029169 0.83 — —
SCHEMBL24616254 0.83 — —
SCHEMBL27053763 0.83 — —
SCHEMBL24616246 0.83 CYP3A4 (0.31) —
SCHEMBL30101999 0.83 — —
SCHEMBL16647241 0.75 — —
SCHEMBL23541046 0.75 CYP1A2 (0.30) —
SCHEMBL31422683 0.75 CYP1A2 (0.30) —
SCHEMBL27053770 0.73 NQO2 (0.31) —
SCHEMBL31491019 0.72 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240140957-A1 BRIDGED COMPOUNDS AS KRAS G12D INHIBITOR AND DEGRADER AND THE USE THEREOF BEONE MEDICINES I GMBH (CH) 2024-05-02 — — US disclosed
WO-2022148422-A1 BRIDGED COMPOUNDS AS KRAS G12D INHIBITOR AND DEGRADER AND THE USE THEREOF BEIGENE, LTD. (KY) 2022-07-14 — — WO disclosed
Send feedback